Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

re: Motley Fool article

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
apostrophe Member Profile
 
Followed By 19
Posts 1,084
Boards Moderated 0
Alias Born 10/17/06
160x600 placeholder
BTIG Remains a Buy on Anavex Life Sciences (AVXL) TipRanks - 1/19/2022 1:45:28 AM
Anavex Life Sciences (AVXL) Gets a Buy Rating from H.C. Wainwright TipRanks - 1/11/2022 6:45:12 AM
JonesTrading Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/10/2022 12:55:34 PM
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71 GlobeNewswire Inc. - 1/10/2022 7:00:00 AM
Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer GlobeNewswire Inc. - 1/6/2022 7:00:00 AM
Anavex Life Sciences Updates 2 Key Risk Factors TipRanks - 1/6/2022 6:01:37 AM
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference GlobeNewswire Inc. - 1/5/2022 7:00:00 AM
Dawson James Maintains a Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/5/2022 4:10:29 AM
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/14/2021 7:00:00 AM
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
apostrophe   Wednesday, 04/06/16 05:14:06 PM
Re: eagle8 post# 58373
Post # of 345458 
re: Motley Fool article

Once again they live up to their name. I notice they end with a pitch for their current "next big thing", which are invariably duds. Better hurry they've only been pushing it for months now. :)

Their target audience seems to be dumb investors. Dumb advice for dumb investors.

The author "He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. " See what I mean? :)

Odd that they would single out AVXL for what amounts to what would be a hit piece for them. Venom isn't really their thing but, big errors of omission in that Anavex is poised to displace Aricept which has a multi-billion dollar market in just the AZ indication and are already getting grants for other indications. Works at least as good with a proven superior safety profile. Considering the FDA approved poisons on the market that pass for "standard of care" treatments for incurable diseases, FDA approval is a foregone conclusion.

100 million authorized shares "means everything" ?! What a crock! It means nothing. Outstanding shares and market cap are actually informative. AVXL has been frugal about issuing shares. We have 36 million and about 40 million fully diluted.

Then he cites cancer bio-techs for comparison. Apples and oranges. How about an actual direct competitor? AXON has 100 million outstanding shares. In spite of the fact that it's a dead company and just hasn't realized it yet, it's about to lose it's main market, share price is on it's way down, but it's still around $15 a share. And this is the author's "worst case" of 100 million shares.

Do the math. Oh, I forgot. We're too "dumb" for that. :)










Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences